Theriva Biologics (TOVX) News
NYSE: TOVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.12-0.008 (-6.25%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TOVX news summary
We found 10 recent headlines mentioning Theriva Biologics (TOVX): 4 in the past week and 10 in the past 30 days, most often from Nasdaq, GlobeNewswire. TOVX is making an outsized move today, down 6.25% at $0.12, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Theriva™ Biologics anuncia una agrupación de acciones", was published by GlobeNewswire on Nov 21, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Theriva Biologics headlines
- Theriva™ Biologics anuncia una agrupación de accionesROCKVILLE, Maryland, Nov. 21, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), una empresa diversificada en fase clínica especializada en el desarrollo de terapias para tratar…GlobeNewswire
- Theriva Biologics, Inc. Announces 1-for-30 Reverse Stock SplitTheriva Biologics, Inc. announced that its Board of Directors approved a 1-for-30 reverse stock split of the Company’s issued, outstanding and authorized common stock. The reverse stock split…Nasdaq
- Theriva™ Biologics Announces Reverse Stock SplitROCKVILLE, Md., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related…GlobeNewswire
- Theriva Biologics, Inc. Stockholders Approve Authorized Share Increase to 500,000,000Theriva Biologics, Inc. held a special meeting of stockholders on November 18, 2026. As of October 9, 2026, the record date for the special meeting, 45,892,688 shares of the common stock were issued…Nasdaq
- Theriva Biologics, Inc. Reports Third Quarter 2026 Results and SYN-004 Asset SaleTheriva Biologics, Inc. completed the sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in October, 2026 for $350,000 upfront and up to $91…Nasdaq
- Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2026– Se prevé que la inscripción en el ensayo VIRAGE2 concluya en el cuarto trimestre de 2026 y que los primeros datos estén disponibles para el tercer trimestre de 2027 –GlobeNewswire
- Theriva Biologics, Inc. Q3 Loss Drops(RTTNews) - Theriva Biologics, Inc. (TOVX) revealed Loss for third quarter of -$1.471 millionNasdaq
- Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results– VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 –GlobeNewswire
- Theriva Biologics Sells Enzyme Portfolio; Shifts Focus To VCN-01; Stock Up(RTTNews) - Theriva Biologics, Inc. (TOVX), a clinical-stage therapeutic company, announced the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), SYN-007, and…NasdaqTOVX, ET
- Theriva Biologics Consensus Price Target Raised 60% to $4.08The average one-year price target for Theriva Biologics (NYSEAM:TOVX) (DB:SFY0) has been revised to $4.08 / share. This is an increase of 60.00% from the prior estimate of $2.55 dated October 20,…Nasdaq